Flagyl is a historical U.S. brand name for metronidazole, but searches for branded Flagyl and currently dispensed generic metronidazole do not always refer to the same marketable product. In particular, the original Flagyl 250 mg and 500 mg branded tablet listings have been discontinued, while approved generic oral metronidazole tablets remain part of the U.S. prescription landscape. A brand name in a database does not confirm the availability of a particular strength or pharmacy package.
This comparison focuses on product equivalence and the distinction between a discontinued brand tablet and a generic tablet with the same active ingredient, dosage form and strength. The 375 mg Flagyl capsule represents a separate capsule presentation, not a synonym for a 250 mg or 500 mg tablet. Review Flagyl brand identity alongside generic metronidazole options to see those product families without assuming stock.
The right purchasing decision begins with an actual prescription. A pharmacist can check current approvals, product strength, manufacturer labeling, substitution rules and availability. Neither the age of a brand nor the lower price sometimes associated with generics is a reason to change the ordered strength, formulation or regimen independently.
The table distinguishes the historical branded Flagyl presentations from generic metronidazole products that may be approved and marketed under their own listings. The important contrast is branded product identity and marketing status versus generic approval, not a claim that a familiar name changes the medical properties of metronidazole.
Check the original brand, exact strength, capsule or tablet form and FDA category before comparing an offered generic. A listed legacy package and a currently dispensable equivalent are different propositions; the pharmacist must identify what can actually be supplied.
| Comparison point | Original Flagyl branded products | Generic metronidazole products |
|---|---|---|
| Ingredient | Metronidazole | Metronidazole |
| 250/500 mg tablets | Original Flagyl tablet brand discontinued | FDA-approved generic tablet presentations exist |
| 375 mg capsule | Separate Flagyl 375 capsule identity | Generic capsule options require product-level confirmation |
| Dosage form | Specific branded tablet or capsule | Specific FDA-approved generic product |
| Substitution question | Identify reference product and status | Confirm identical route/form/strength and TE where applicable |
| Can inventory be inferred from FDA records? | No | No |
The FDA Orange Book discontinued section tracks certain products that are no longer marketed, but discontinuation is not automatically a statement that a drug was withdrawn for safety reasons. Flagyl 250 mg and 500 mg branded oral tablet listings should be discussed in this historical product context. Their presence in older prescribing information does not create a current storefront offer.
Generic oral metronidazole tablets can still be approved and marketed independently of the old brand tablet. A user who sees a pharmacy search result labeled “Flagyl generic” should confirm that the listed item is the right generic metronidazole tablet, not assume a discontinued brand package will be delivered.
An FDA-approved generic of a specific brand product must meet requirements for active ingredient, strength, dosage form, administration route and bioequivalence. Generics may differ in permitted inactive ingredients or appearance. These standards support substitution within appropriate product categories; they do not mean that every product containing metronidazole is interchangeable.
A 375 mg capsule, an extended-release tablet and an immediate-release tablet should not be grouped under one undifferentiated “generic Flagyl” SKU. Where an FDA therapeutic-equivalence determination applies, the pharmacist still considers the written prescription and state substitution rules. See the tablet-form guide for distinct 250/500 mg products.
The Flagyl 375 capsule is an actual distinct dosage-form identity. Its label describes a 375 mg oral capsule, while common generic immediate-release tablets are represented at 250 mg and 500 mg strengths. The number of milligrams written on a prescription cannot be separated from the dosage form.
Searching for a 375 mg capsule when a patient holds a 500 mg tablet prescription will not produce a direct pharmacist-approved substitution. The capsule product guide and tablet-versus-capsule comparison describe the difference without advising a dose conversion.
Brand recognition is not evidence of superior safety, guaranteed availability or a higher quality of approved generic metronidazole. A medicine dispensed through a licensed U.S. pharmacy must be matched to the active ingredient, route, formulation and prescription; the brand may be unavailable while a clinically appropriate generic exists.
It is also misleading to generalize a tablet discontinuation to all forms of metronidazole or to branded products serving unrelated routes. MetroGel for skin and vaginal products have separate labels and brand histories. This page addresses Flagyl and its corresponding oral generic context only.
A generic prescription label typically records “metronidazole,” a particular strength, a tablet or capsule form, quantity, directions and manufacturer or product identifiers. Those details matter more than a retailer’s use of “Flagyl” as a search keyword. If the label or package differs from the written order, ask the dispensing pharmacist for a careful check.
Price comparisons should likewise use the same strength, quantity and form. A tablet priced per unit is not directly comparable with a liquid bottle or a different-strength capsule. The oral cost-factor guide deals with those distinctions separately from the regulatory history of a brand.
If a prescription explicitly specifies a legacy Flagyl tablet presentation, ask the pharmacist and prescriber to review current approved products. The correct answer is a verified prescription decision, not an unsupported claim that a branded package remains obtainable from a distant pharmacy.
Do not reuse historical instructions, change dosage forms or accept unlabeled products sold as imported Flagyl. Licensed pharmacies should require prescriptions and disclose the medicine actually dispensed. A product record may establish approval or a discontinued category; it does not prove local inventory.
The active ingredient metronidazole has meaningful contraindications, warnings and potential interactions, regardless of whether an approved product uses a brand or generic label. The exact package insert should be reviewed for the medicine prescribed, especially with relevant medical history or concurrent medicines.
Generic status does not make an antibiotic appropriate for a new infection or justify self-prescribing. Clinical evaluation determines whether metronidazole is suitable and which regimen applies. Report concerning reactions rather than trying a different manufacturer or dosage form as an unsupervised workaround.
Pharmacy search engines may retain Flagyl as a synonym for metronidazole even when the item that could be dispensed is generic. This can be a useful search convenience if the actual product is identified transparently, but it becomes misleading when a historical branded tablet name is shown without a current brand-specific inventory or package.
The final prescription label, rather than the search result title, should disclose the active drug, strength, form and product dispensed. The safest pharmacy interaction is to ask which exact product will be supplied and whether the substitution is allowed.
A patient with an old Flagyl prescription can ask the pharmacy to identify the intended oral form, strength and directions, then confirm whether the particular branded item remains marketed. If not, the pharmacist can check current FDA-approved generic products in the appropriate category and determine whether the order permits substitution or requires a prescriber clarification. The historical brand does not need to be presented as an available retail purchase to make the page useful.
When the replacement is discussed, confirm how the final prescription will describe the medicine and what name will appear on the dispensed label. A patient should be able to understand why a generic tablet can be appropriate while a similarly named capsule, vaginal gel or extended-release formulation is not an assumed replacement.
Yes. Flagyl is a brand name historically used for metronidazole, but a particular brand product and a generic must still be compared by form and strength.
The original branded 250 mg and 500 mg tablet products are listed as discontinued; that does not mean approved generic metronidazole tablets have disappeared.
Yes. FDA-approved generic oral metronidazole tablets exist, subject to particular applications and product records.
Flagyl 375 is a capsule product identity, distinct from standard 250 mg and 500 mg tablets.
Not necessarily. A discontinued marketing record alone does not establish a safety-related withdrawal.
No. Equivalence requires an appropriate match in ingredient, route, dosage form, strength and applicable FDA evaluation.
A pharmacist can check whether a particular FDA-approved generic can lawfully satisfy the prescription or whether prescriber authorization is needed.
Appearance and permitted inactive ingredients can differ; verify the actual dispensed product with the pharmacist.
No. FDA status and actual inventory are different facts.
Do not change the form or strength without the prescriber and pharmacist assessing the intended regimen.